Elsevier

Virology

Volume 175, Issue 1, March 1990, Pages 211-221
Virology

The hemagglutinin-neuraminidase glycoproteins of human parainfluenza virus type 1 and Sendai virus have high structure-function similarity with limited antigenic cross-reactivity

https://doi.org/10.1016/0042-6822(90)90201-2Get rights and content

Abstract

Human parainfluenza virus type 1 (hPIV-1) is closely related to Sendai virus on the basis of cross-reactivity of antisera. We examined this association further by using monoclonal antibodies to the Sendai virus hemagglutinin-neuraminidase (HN) glycoprotein to determine the relationship between overall protein structure and the hemagglutination and neuraminidase functions. Of 10 monoclonal antibodies representing four nonoverlapping antigenic sites on the HN of Sendai virus, only 4 from two sites cross-reacted with hPIV-1, indicating a limited conservation of epitopes. One of these four inhibited the hemagglutinating activity of hPIV-1 comparably to Sendai virus, but none appreciably inhibited the neuraminidase activity of hPIV-1. The ability of some of these monoclonal antibodies to inhibit only hemagglutinating or neuraminidase activity of either virus provided evidence for two separate active sites on the HN molecule. To determine the overall structural relationship of the HNs of hPIV-1 and Sendai virus, we cloned and sequenced the HN gene of hPIV-1. The HN clone was made from genomic RNA and was identified by hybrid-arrested in vitro translation of mRNA. The predicted HN protein sequence of hPIV-1 was identical in length to that of Sendai virus and had a shared identity of 72%. There was a marked conservation of structural elements (cysteines, prolines, and glycines), which would predict a similar molecular conformation. However, there were 10 potential glycosylation sites on the HN of hPIV-1, compared with 5 on Sendai virus. Some of these sites may be responsible for the inability of the Sendai virus monoclonal antibodies to cross-react. The results of our study support a close structure-function relationship between hPIV-1 and Sendai virus but suggest limited antigenic cross-reactivity.

References (44)

  • A. Portner

    The HN glycoprotein of Sendai virus: Analysis of site(s) involved in hemagglutinating and neuraminidase activities

    Virology

    (1981)
  • A. Portner et al.

    Distinct functions of antigenic sites of the HN glycoprotein of Sendai virus

    Virology

    (1987)
  • R. Ray et al.

    Monoclonal antibodies reveal extensive antigenic differences between the hemagglutinin-neuraminidase glycoproteins of human and bovine parainfluenza 3 viruses

    Virology

    (1986)
  • J.S. Robertson et al.

    Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs

    Virology

    (1985)
  • S.D. Thompson et al.

    Localization of the functional sites on the HN glycoprotein of Sendai virus by sequence analysis of antigenic and temperature-sensitive mutants

    Virology

    (1987)
  • M. Aymard-Henry et al.

    Influenza virus neuraminidase and neuraminidase-inhibition test procedures

    Bull. WH0

    (1973)
  • M.D. Biggin et al.

    Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination

  • R.M. Chanock et al.

    Newly recognized myxoviruses from children with respiratory disease

    N. Engl. J. Med.

    (1958)
  • R.M. Chanock et al.

    Parainfluenza viruses

  • K.J. Coelingh et al.

    Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: Nucleotide sequence analysis of variants selected with monoclonal antibodies

    J. Virol.

    (1986)
  • K.L.V.W. Coelingh et al.

    Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of the human parainfluenza virus type 3: Sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities

    J. Virol.

    (1987)
  • K.L.V.W. Coelingh et al.

    Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge

    J. Infect. Dis.

    (1988)
  • Cited by (84)

    • Timing is everything: Fine-tuned molecular machines orchestrate paramyxovirus entry

      2015, Virology
      Citation Excerpt :

      In NDV HN and hPIV3 HN, evidence has been presented of a second sialic acid binding site, which lacks neuraminidase activity (Bousse et al., 2004; Mahon et al., 2011; Porotto et al., 2012b; Zaitsev et al., 2004). An atomic structure of the globular head domain of NDV HN from a low virulence (lentogenic) strain (Ulster) (Yuan et al., 2012) showed a longer C-terminal extension (Gorman et al., 1990; Nagai et al., 1976; Sakaguchi et al., 1989) that was found to be involved in auto-inhibition of receptor binding by obscuring both the primary and secondary sialic acid receptor binding sites of NDV HN (Yuan et al., 2012). Proteolytic cleavage of this C-terminal extension is required for receptor binding and fusion in these NDV strains (Yuan et al., 2012).

    • Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model

      2014, Vaccine
      Citation Excerpt :

      A study was designed and approved by Institutional Review Boards to collect sera from inpatient infants at Le Bonheur Children's Hospital (Memphis, TN) for testing in RSV-specific and SeV-specific neutralization antibody assays. SeV-specific antibodies are present among maternal antibodies, because most humans are exposed repeatedly to hPIV-1, a virus closely related to SeV [36]. In Table 1 are shown neutralization titers from 14 representative serum samples in age groups 0 to ≤2 months, 2 to ≤4 months, and 4 to ≤6 months.

    • Distinctive and critical roles for cellular immunity and immune-inflammatory response in the immunopathology of Sendai virus infection in mice

      2011, Microbes and Infection
      Citation Excerpt :

      The occurrence of this “cytokine storm” is thought to contribute to the severity of the disease caused by these viruses [3–6]. Sendai virus (SeV) is the murine counterpart of human parainfluenza virus 1 (HPIV1) and these two viruses share high-sequence homology and antigenic cross-reactivity [7,8]. SeV was reported to infect nonhuman primates, and theoretically can cause zoonotic disease in humans [9].

    • Phenotypes and functions of persistent Sendai virus-induced antibody forming cells and CD8<sup>+</sup> T cells in diffuse nasal-associated lymphoid tissue typify lymphocyte responses of the gut

      2011, Virology
      Citation Excerpt :

      Sendai virus (SeV), a natural pathogen of mice (Faisca and Desmecht, 2007) is endemic in many parts of the world, yet there have been no confirmed reports of SeV-mediated disease in humans. Based on sequence homology SeV is closely related to hPIV-1 (McCarthy and Goodman, 2010; Power et al., 1992; Gorman et al., 1990; Lyn et al., 1991). The two viruses are also well related in terms of B and T cell cross-reactivities (Dave et al., 1994; Smith et al., 1994).

    • Robust IgA and IgG-producing antibody forming cells in the diffuse-NALT and lungs of Sendai virus-vaccinated cotton rats associate with rapid protection against human parainfluenza virus-type 1

      2010, Vaccine
      Citation Excerpt :

      Whereas SeV was originally thought to be the etiologic agent of human disease [6,7], researchers have since determined that it is a pathogen of mice and not of humans [8]. During laboratory studies of SeV, the profound sequence and antigenic similarities between SeV and hPIV-1 were recognized [9–12], as was the potential for SeV to serve as a Jennerian (xenotropic) vaccine for protection against hPIV-1. SeV has been shown to grow transiently in the upper and lower respiratory tract of non-human primates, conferring complete protection against hPIV-1 challenge with no evidence of adverse events [13,14].

    View all citing articles on Scopus
    View full text